Antibodies to topoisomerase-I are present in approximately 26% of patients with scleroderma and are rarely found in patients with other diseases. In the current study, the expression of the antitopoisomerase-I (antitopo-I) idiotype from two scleroderma patients (E.M. and S.G.) and from a healthy individual (N.M.) were studied. Idiotype EM-SCL was restricted to the three classes of antitopo-I, whereas idiotypes SG-SCL and NM were found in all classes of antitopo-I as well as in their non-antitopo-I Igs. Sera from 9 of 10 antitopo-Ipositive unrelated scleroderma patients expressed idiotype SG-SCL and some also expressed idiotype NM. Sera from N.M.'s 3 daughters and from 7 of 18 nonrelated normals expressed idiotype NM in the three immunoglobulin classes of non-antitopo-I. Two of the antitopo-I antibodies expressed a cross-reacting idiotype (CRI) that is present in nonantitopo-I antibodies from the same donor. Contrary to the natural CRI, SG-SCL's CRI is closely associated with the antigen binding site. Antitopo-I idiotypes are on the heavy chains. Like many other autoantibodies, Id-SG-SCL use VH4.2-1, DXP1, and JH4 in germline configuration. were studied. Idiotype EM-SCL was restricted to the three classes of antitopo-I, whereas idiotypes SG-SCL and NM were found in all classes of antitopo-I as well as in their non-antitopo-I Igs. Sera from 9 of 10 antitopo-I-positive unrelated scleroderma patients expressed idiotype SG-SCL and some also expressed idiotype NM. Sera from N.M.'s 3 daughters and from 7 of 18 nonrelated normals expressed idiotype NM in the three immunoglobulin classes of non-antitopo-I. Two of the antitopo-I antibodies expressed a cross-reacting idiotype (CRI) that is present in non-antitopo-I antibodies from the same donor. Contrary to the natural CRI, SG-SCL's CRI is closely associated with the antigen binding site. Antitopo-I idiotypes are on the heavy chains. Like many other autoantibodies, Id-SG-SCL use VH4.2-1, DXP1, and JH4 in germline configuration. (J. Clin. Invest. 1993. 92:1302-1313
Introduction
Scleroderma is a rare disease occurring in 19-75 per 100,000 individuals ( 1 ) . Antitopoisomerase-I (antitopo-I)' (2-4) is present in sera from -26% ofthe scleroderma patients (5, 6) . These autoantibodies to topoisomerase-I (topo-I) can be detected by immunoblotting on HeLa nuclei or chromosomes, by double immunodiffusion, by enzyme inhibition (3) , or by a recently standardized ELISA (7) . The different sensitivities and specificities of these tests may account for the differences 1 . Abbreviations used in this paper: antitopo-I, antitopoisomerase I; C, constant; CA, cold agglutinins; CDR, complimentarity determining region; CRI, cross-reactive idiotype; D, diversity; FT, flow through; HRP, horseradish peroxidase; NHS, normal human serum; PCR, polymerase chain reaction; RF, rheumatoid factor; topo-I, topoisomerase I; V, variable. in reported prevalence of antitopo-I in scleroderma patients (7) . Topo-I catalyzes the breaking/rejoining ofsingle-stranded DNA and relaxes supercoiled DNA in vitro (3, 4, (8) (9) (10) . The enzymatically active site is expressed in the 67.7-kD carboxyterminal fragment (8) between amino acids 344 and 483 ( 1). Topo-I has a native molecular mass of 100 kD, but smaller proteolytic products ranging from 60 to 100 kD are functionally active (2-15). The major protein isolated from calf thymus is 70 kD (2) . Antibodies to topo-I bind one or more ofsix epitopes in the enzyme ( 13) and inhibit the enzyme's activity in vitro (3, 4, 7, (9) (10) (11) (12) .
Antitopo-I is highly specific for scleroderma (4) (5) (6) (7) (13) (14) (15) . We have found antitopo-I in only 1 of 264 healthy controls (5, 15) . This healthy 64-yr-old female (N.M.) has not developed any sign or symptom related to scleroderma or to any other connective tissue disease over the past 8 yr while the antitopo-I has been in her serum.
In our previous idiotypic analysis ofhuman antitopo-I ( 15) we described the presence of at least one immunodominant private idiotype (Id) in or near the antigen binding site. In that report we characterized the antitopo-I Id from scleroderma patient EM-SCL. Id-EM-SCL was stable for the period of 9 yr of follow-up and was not expressed in sera from any of 29 antitopo-I-positive patients, 10 anticentromere-positive patients, 10 negative antitopo-I and negative anticentromere patients, or 20 healthy controls ( 15). The antitopo-I Ids from the SG-SCL and from the healthy individual N.M. did not cross-react with the purified preparations from any ofthe other two antitopo-Ipositive sera (SG and EM), three anticentromere-positive sera, or with a panel of human myeloma and monoclonal Igs.
We report here that (a) Ids were expressed in all the Ig classes of antitopo-I EM-SCL, SG-SCL, and NM; (b) Id-SG-SCL and Id-NM are also expressed in their non-antitopo-I Igs; (c) positive antitopo-I sera from nonrelated scleroderma patients expressed one or both cross-reacting Ids (CRIs); and (d) CRI NM was also expressed in the IgG, IgM, and IgA of her 3 daughters' sera and in different Ig classes from 7 of 18 unrelated control sera.
Our results show that antitopo-I antibodies express immunodominant Ids located in the heavy chains that are stable after isotype switch. The private Id from the scleroderma patient, EM-SCL, was specific for antitopo-I antibodies. Both Id-EM-SCL and Id-SG-SCL may be close to the antigen binding site. In contrast the expression ofId-NM is more likely to be contributed by framework region residues and thus is able to bind to anti-Id even after binding to topo-I.
We cloned the variable region heavy chain (VH) gene bearing the CRI from SG-SCL and found that it uses VH4.2-1, DXP1, and junctional region heavy chain JH4 in germline configuration. Addition of one amino acid at each of the diversity (D) region boundaries by N sequences is the only difference from the germline configuration at the complementarity determining region 3 (CDR3). The presence of a private Id in EM-SCL may be the product of somatically mutated heavy chain genes in an individual response to the autoantigen.
Methods
The patients EM-SCL and SG-SCL's clinical features have been described elsewhere ( 15 ). N.M. is a healthy 65-yr-old white female with antitopo-I whom we have followed for 8 yr.
Preparation of affinity-purified antitopo-L Antitopo-I from EM-SCL, SG-SCL, and NM were prepared by affinity purification, as previously described ( 15). Briefly, whole patient serum from the patients was extensively absorbed with topo-I isolated from calf thymus (7) coupled to Sepharose 4B gel (Pharmacia, Uppsala, Sweden). Eluted fractions were concentrated and flow throughs (FT) were used in final diluted fractions. In total, 10 purified antitopo-I antibodies from EM-SCL, 5 from SG-SCL, and 6 from NM as well as 2 Fls from EM-SCL and 3 from SG-SCL and NM were studied.
Preparation of anti-Ids. Anti-Id sera was prepared as previously described ( 15). Briefly, two Pasteurella-free New Zealand white rabbits were immunized with 100-150 ,g ofeither SG-SCL-purified antitopo-I, NM antitopo-I, or EM-SCL antitopo-I. Booster immunizations were carried out at week 2 and then at monthly intervals. The animals were bled 15 d after the final boost (total of three for all rabbits except for one of the two EM-SCL rabbits). This EM-SCL rabbit received a total of 700 ytg in six booster injections. Igs were precipitated with 40% saturated ammonium sulfate, dialyzed overnight at 40C with PBS, and exhaustively adsorbed with a mixture of human myeloma IgG, IgM, and IgA (gift from Dr. Blas Frangione, New York University School of Medicine) coupled to Sepharose 4B gel (Pharmacia). After further adsorption with normal human serum (NHS) depleted of Ig (Sigma Chemical Co., St. Louis, MO) coupled to Sepharose 4B (Pharmacia) the FT fractions were absorbed with Staphylococcal protein A (Sigma Chemical Co.) coupled to Sepharose 4B (Pharmacia). Fractions were eluted with a 0.2 M glycine buffer, pH 1.9, and immediately were neutralized, pooled, and concentrated by vacuum dialysis with PBS at40C.
Seven anti-Ids from the two rabbits immunized with EM-SCL antitopo-I, five from SG-SCL's rabbits, and six from N.M.'s rabbits were studied. All anti-Ids from the homologous antitopo-I-purified sample behaved and were expressed in the same manner.
Control anti-Ids reagents were prepared by ammonium sulfate precipitation of Igs from each preimmunized rabbits' sera. These were absorbed with Staphylococcal protein A (Sigma Chemical Co.) coupled to Sepharose 4B (Pharmacia) and concentrated by vacuum dialysisat4°C.
Detection of antitopo-L SDS-PAGE gels were performed as described ( 16) using Western blot and either HeLa chromosome extracts or purified topo-I (7, 17) . Blots on topo-I were developed with 125I Staphylococcal protein A (Amersham Corp., Arlington Heights, IL) for IgG detection after incubation with the purified samples. For detection of IgM and IgA after incubation with the purified samples, strips were incubated with horseradish peroxidase (HRP) rabbit antihuman, mu chain, or alpha chain-specific antibodies (Dakopatts, Copenhagen, Denmark) and developed with high sensitivity IBI enzygraphic web (Kodak, International Biotechnologies, Inc., New Haven, CT). Blots on HeLa chromosome extracts were blocked 1 h at room temperature, incubated with antitopo-I-positive sera at a dilution of 1:1,000 1 h at room temperature as previously described (3). They were then incubated with HRP anti-human gamma, mu, or alpha chain-specific antibodies (Dakopatts) 1 h at room temperature and developed with the ECL system (Amersham).
The topo-I functional assay was performed on a 1.2% agarose DNA gel as described (3, 7 ,g/ml of the respective FTs. HRP-conjugated rabbit antibodies to human gamma chain (1:5,000), anti-human mu, or alpha chains (1:2,000) were added. The amount of IgG, IgM, and IgA in each sample was determined by plotting the mean of each sample's triplicate on the standard curves and adjusting for each sample's dilution factor. or buffer alone and added to plates precoated with 0.5 Ag/ml oftopo-I.
HRP-conjugated rabbit anti-human gamma, mu, or alpha chain-specific antibodies (Dakopatts) was added and plates were developed as described. Percentage inhibition was calculated using the formula:
{ [nonblocked OD (preincubated with buffer) -blocked OD (preincubated with topo-I)]/(nonblocked OD)} x 100. Detection ofIgG, JgM, and IgA Id. Optimal concentrations ofeach purified antitopo-I or 10 times the respective FT was incubated with homologous anti-Id. These samples were added to plates precoated with homologous anti-Id. Specific HRP-conjugated rabbit antibodies to human gamma, mu, or alpha chain were used as above. Percentage inhibition was calculated as above.
Relationship between Id and antigen binding site. EM-SCL, SG-SCL, NM, or the respective FTs were incubated with homologous antiId or preimmune IgG at optimal concentrations and added to plates precoated with topo-I (0.5 ug/ml). Plates were then incubated with specific HRP-conjugated rabbit antibodies to human gamma, mu, or alpha and were developed as above. Percentage inhibition was calculated as described above.
The blocking by topo-I of the binding of Id to homologous anti-Id was evaluated by incubating each purified antitopo-I or the respective FT with topo-I or buffer and added to plates precoated with homologous anti-Id. Specific HRP-conjugated rabbit antibodies to human gamma, mu, or alpha were added and plates were developed as above. Percentage inhibition was calculated as above.
Blocking studies using varying amounts ofanti-Id. EM-SCL, SG-SCL, NM, or the respective FTwas incubated with 10 serial dilutions of homologous anti-Id and tested on topo-I precoated plates. After incubation and addition of specific HRP-conjugated rabbit antibodies to human gamma, mu, or alpha, plates were developed as above. Percentage inhibition was calculated for each anti-Id concentration and results plotted on a graph as logarithm of the reciprocal dilution in micrograms per milliliter vs. percent inhibition. Blocking studies using varying amounts of top( SCL, NM, or the respective FT was incubated with 14 topo-I starting with 1 1g/ml and added to plates co gous anti-Id as described. Specific HRP-conjugated r human gamma, mu, or alpha were added and plates above. Percentage inhibition was calculated and above.
Detection ofId-NM in controlsera. NHS, sera fro ters, and from 18 nonrelated controls all lacking a were each incubated as above at 1:600 dilution with anti-Id-NM or preimmune rabbit's Ig. NM whole serum was used as the positive control. The samples were added to plates precoated with anti-Id NM. Specific HRP-conjugated rabbit antibodies to human gamma, mu, or alpha were added and plates were developed as above. Percentage inhibition was calculated as mentioned.
Detection ofId in antitopo-Ifrom other patients. Immunoblots using HeLa chromosome extracts were incubated with 1:1,000 of 10 antitopo-I-containing sera from scleroderma patients. Blots were developed using the electrochemiluminesence system after incubating with either anti-Id SG-SCL or anti-Id NM. SG-SCL-and NM-purified antitopo-I were used a positive controls and their respective FTs as negative controls.
EBV-transformation ofS.G. 's B cells. Ficoll/ Hypaque fractionated peripheral blood cells from patient S.G. were transformed in the presence of 50% EBV-rich supernatant in 96-well plates, as described ( 19) . When FTs were used 10 times more concentrated than the or NM-FT with respective purified antitopo-I, no inhibition of topo-I activity ified Ig.
was found (results not shown). Fig. 1 Fig. 3 A. Ig classes ofId. Id from each patient's antitopo-I was expressed in all Ig classes of antitopo-I. Fig. 3 These results were confirmed by immunoblots on each of the purified samples ofId. When the blots were incubated with homologous anti-Id, bands corresponding to gamma, alpha, and mu chains were visualized for each of the purified antitopo-I samples (Fig. 4 A) Both proteins reacting with the specific anti-human gamma chain also react with the anti-Id. Anti-Ids to SG-SCL and NM were expressed by the non-antitopo-I Ig oftheir respective FTs and in commercial IgG kappa (Sigma). None ofthe three antiIds bound to the light chain of antitopo-I (Fig. 4 B) . The blots were negative when incubated with preimmune rabbits' purified Igs (results not shown).
To assess whether Ids to SG-SCL and NM were expressed in other antitopo-I antibodies, immunoblots on HeLa chromosomes using whole sera from 10 nonrelated positive antitopo-I scleroderma patients were performed. As shown in Fig. 5, 9 of 10 expressed Id-SG and some of these coexpressed Id-NM (lane 12 is too dark to detect a specific band at 100 kD). The more intense bands using Id-SG may reflect the higher titers, which were obtained in a direct binding ELISA (results not shown).
The presence of NM-Id in the IgG, IgM, and IgA from N.M.'s 3 daughters' sera and sera from 18 healthy nonrelated controls was studied using blocking ELISA. As shown in Fig. 6 A, all three daughters' Ig classes caused meaningful inhibition (25-73%) of Id/anti-Id binding. When 18 unrelated normal controls were tested, 7 inhibited 35% and 9 20% (Fig. 6 B) .
Thus Id-SG-SCL is expressed in antitopo-I (+) sera and Id-NM is expressed both in antitopo-I (+) sera as well as in all three classes of Ig populations devoid of antitopo-I activity in genetically unrelated and in related individuals.
Relationship between Id and antigen binding site. Fig. 7 A shows the blocking percentage of antitopo-I binding to topo-I by homologous anti-Id for all classes of antitopo-I in EM-SCL, SG-SCL, and NM. Anti-Ids also blocked the inhibition oftopo-I uncoiling of DNA by antitopo-I in the functional assay (Fig.  8) . We have previously assayed every anti-Id on DNA alone, and none of the rabbit's anti-Ids was enzymatically active in uncoiling DNA (25) (anti-Id's NM results shown in Fig. 8, lane  4) ; thus, the uncoiled DNA in lane 7 is the result of topo-I activity that is not inhibited by Id-NM after incubation with anti-Id-NM. Fig. 7 B shows that topo-I blocked the binding of all three classes of antitopo-I EM-SCL and SG-SCL to homologous anti-Id. In contrast, topo-I did not block NM's binding to homologous anti-Id.
To investigate whether there is a higher affinity for the antiId-NM than for topo-I or whether Id-NM is independent ofthe antigen binding site, blocking studies were carried out using varying amounts of homologous anti-Id as inhibitor. Fig. 9 A shows the dose-dependent inhibition of all classes of antitopo-I EM-SCL, SG-SCL, and NM. In the reverse experiment, topo-I was used to inhibit the binding of Id to homologous anti-Id (Fig. 9 B) VH gene use by SG monoclonal antibodies. All 12 clones studied amplified VH4 family genes (Fig. 10) . After transformation of competent E. coli and ligation into bluescript plasmid, a total of 14 ssDNA were sequenced from eight clones. All sequences were identical (Fig. 11 ) and corresponded to the germline genes VH4.2-1, DXP1, and JH4. When the amino acid sequence was analyzed, the only substitutions were in the boundaries of the D segment, where one amino acid had been added from the N sequences in the rearranged gene (Fig. 11) .
Discussion
Antitopo-I is a highly specific autoantibody originally described in patients with scleroderma (4-7, 13-15). Although found in approximately one-third ofthese patients, its presence for the existence of two types of autoantibody idiotypes: one private idiotype uniquely associated with antitopo-I antibodies in patients with scleroderma, and one CRI present on antitopo-I of other scleroderma patients, as well as on non-antitopo-I Ig from these patients and unrelated healthy individuals.
We detected the expression ofthe private scleroderma-associated Id-EM-SCL using polyclonal Id-EM-SCL (+) antibodies as they occur in the patient's serum and rabbit polyclonal antiIds. Id-EM-SCL is expressed mainly in IgG and IgA and to a lesser extent in IgM. The fact that polyclonal anti-Ids do not react with any other Id present in non-antitopo-I Igs from the same donor or in antitopo-I from nonrelated patients (15) strongly suggests the presence in scleroderma EM-SCL antitopo-I of a true private Id. By Western blot Id-EM-SCL is expressed on the heavy chains. Since it is stable after class switch, we can rule out the identification of an allotypic marker or an Id close to the J/constant (C) region boundary. Thus Id-EM-SCL is most likely near one or several CDRs. Moreover, antigen and anti-Id competition experiments suggest that Id-EM-SCL may be close to but not in the antigen binding site.
Unlike Id-EM-SCL, natural NM antitopo-I antibodies express a CRI that is not specific for antitopo-I since it is expressed in homologous non-antitopo-I Igs as well as in non-antitopo-I Igs from related and unrelated individuals. Contrary to that found with the scleroderma-associated Ids, topo-I did not interfere with the natural CRI-NM expression, suggesting that the structural determinants ofNM idiotype expression are outside the antigen binding site. The findings in NM are similar to those reported for murine antitopo-Ids from a mouse model of scleroderma (26, 27) . As in our natural idiotype NM, topo-I did not block the binding of murine antitopo-I antibodies to murine anti-Id (26) .
Both scleroderma-associated Ids (the private Id-EM-SCL and the CRI-SG-SCL) differ from the natural CRI-NM in their association with the antigen binding site. In both cases, the binding to autoantigen altered the capacity of the idiotype to interact with the homologous anti-Ids and vice versa.
We have previously reported that neither NM or EM-SCL express Id-SG-SCL nor SG-SCL expresses the CRI-NM or Id-EM-SCL ( 15 ). We here carried out additional experiments and now are able to demonstrate that Id-SG-SCL is expressed in her non-antitopo-I Igs and that other antitopo-I molecules from unrelated scleroderma patients may express this CRI-SG-SCL with or without CRI-NM.
The presence of private and public Ids as well as the independent expression of different CRIs has been reported to occur in several autoantibody responses like rheumatoid factors (RF) and cold agglutinins (CA) (28) (28, 29, 45) .
The origin of autoantibodies is still a controversial issue. The Ig molecule results from VH and VL gene rearrangements occurring early in B cell maturation and from somatic changes that take place later in B cell development (57, 58) . The fetal and neonatal B cell repertoires include genes that have been shown to encode self-reactive antibodies (34, (46) (47) (48) (57) (58) (59) and some ofthese genes have been proposed to play an important role in immune regulation and development of normal immune repertoire (34-36, 46, 48, 57-59) . Autoreactivity could be a result of immune disregulation leading to the overexpression of particular self-reactive germline Ig genes (34-37, 46, 47, 57, 59-63) . On the other hand it has been suggested that autoantibodies result from an antigen-driven process, i.e., the autoantigen selects those somatically mutated B cell clones that produce an antibody with highest affinity for the antigen. This second view is supported by similarities of disease-associated autoantibodies to the antibodies found in the secondary immune response (38, 49, 50, (63) (64) (65) (66) (67) (68) (69) Our data show that all the IgM kappa antitopo-I from SG-SCL clones expressed the same CRI-SG-SCL found in the serum. Furthermore, we showed that all classes of CRI-SG-SCL (+) serum antitopo-I displayed similar dose-response curves on inhibition studies most likely with similar avidities and affinities for the autoantigen as well as for the anti-Ids. Thus the VH-associated CRI-SG-SCL is likely encoded by the same or very similar germline gene in the B cells secreting different classes of antitopo-I.
Studies ofCAs from different individuals has suggested that anti-red blood cells responses are restricted in the usage ofthe VH4-2 1-encoded CRI. Since the anti-Id blocks both the binding and cold agglutination, this CRI may be close to the CDRs (33, 55 ) . The high prevalence ofVH4-2 1-encoded autoreactive antibodies (70) and the binding of protein A to the VH3 region of Igs ( 18) have raised the novel concept of a nonconventional antigen binding site for autoantigens (70) . The specificity for antitopo-I could thus be within this VH4 gene. The future molecular analysis ofother scleroderma antitopo-I producers from nonrelated individuals, including NM, will define if there is indeed a preferential use of this or other VH4 family member and ifthere is an association between the expression ofCRI-SG and disease. It has been suggested that disease-associated IgG autoantibodies may originate from 1gM precursors that belong to the pool of natural autoantibodies (71, 72) . Some of these disease-associated autoantibodies have undergone class switch and presumably accumulate somatic mutations that increase the affinity for the autoantigen (64) (65) (66) (67) and at the same time modify the expressed Id rendering it private (39, 51, 52, 61, 62, 64, 65, 68, 69) .
It will be important to identify the gene used by CRI-NM, which may be a non-self-reacting germline gene. It will also be necessary to determine whether other anti-topo-I antibodies that share the CRI-SG use the VH4-2.1 germline gene. Such antibodies would then be different from CRI-NM. In this case, CRI-SG may be encoded by an autoreactive VH germline gene combination that has been either autoantigen-selected (60) or expressed after a deletion of a closer, non-self-reactive gene (36) , by other immune disregulation at the idiotype network, or at the T cell level (67, (70) (71) (72) .
In summary, the idiotypic studies presented herein are consistent with the notion that autoantibodies sharing the same specificity can be encoded by either germline genes or genes that have undergone a process of somatic mutation. It is likely that antigen-driven selection of certain somatically mutated B cells may be responsible for the emergence of private idiotypes and possible escape from idiotype network regulation.
The fact that both types ofautoantibodies were found in the limited number ofpatients studied also suggests that it may not be unrealistic to imagine that both private idiotypes and CRIs may coexist in the same patient and that the expression of germline genes plays a protective role against the emergence of somatically mutated autoreactive clones (72) .
